Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Determine the Relative Bioavailability of BOS172767 Enantiomer E1 and E2 and the Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Selected Enantiomer in Healthy Subjects

NCT04514237 is registered in ClinicalTrials.gov with Boston Pharmaceuticals as lead sponsor.

NCT NCT04514237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04514237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Determine the Relative Bioavailability of BOS172767 Enantiomer E1 and E2 and the Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS172767 Selected Enantiomer in Healthy Subjects
Lead sponsor
Boston Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
September 12, 2019
Completion date
January 22, 2020
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants